The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors.
 
Mikiya Ishihara
Honoraria - Chugai Pharma; Eisai; Novartis; Takara Bio
Research Funding - Eisai (Inst)
 
Yasutaka Tono
No Relationships to Disclose
 
Yoshihiro Miyahara
Research Funding - Takara Bio (Inst)
 
Naozumi Harada
Leadership - United Immunity
Stock and Other Ownership Interests - United Immunity
Research Funding - Chugai Pharma (Inst)
 
Shinichi Kageyama
Research Funding - Takara Bio (Inst)
Expert Testimony - Takara Bio
 
Takeshi Sasaki
No Relationships to Disclose
 
Yasuhide Hori
No Relationships to Disclose
 
Norihito Soga
No Relationships to Disclose
 
Katsunori Uchida
No Relationships to Disclose
 
Taizo Shiraishi
No Relationships to Disclose
 
Eiichi Sato
No Relationships to Disclose
 
Hideki Kanda
No Relationships to Disclose
 
Toshiro Mizuno
Honoraria - AstraZeneca Japan; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Novartis; Ono Pharmaceutical
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical
 
Gill Webster
Employment - Innate Pharma
Leadership - Innate Pharma
Stock and Other Ownership Interests - Innate Pharma
Research Funding - Innate Pharma
Patents, Royalties, Other Intellectual Property - Innate Pharma
Travel, Accommodations, Expenses - Innate Pharma
 
Hiroaki Ikeda
Research Funding - Takara Bio (Inst)
 
Naoyuki Katayama
Honoraria - Alexion Pharmaceuticals; Astellas Pharma; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Janssen; Kyowa Hakko Kirin; Nippon Shinyaku; Novartis; Novo Nordisk; Pfizer; Shionogi; Shire; Sumitomo Dainippon; Sysmex; Taisho Toyama Pharma; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Novo Nordisk (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst)
 
Yoshiki Sugimura
No Relationships to Disclose
 
Hiroshi Shiku
Speakers' Bureau - AstraZeneca
Research Funding - Takara Bio (Inst)